Clinical Trials Logo

Clinical Trial Summary

The primary objective of the study is to select the dose of AVE1642 to be administered in patients with liver carcinoma not eligible for local treatment.

The secondary objectives of the study are:

- To evaluate the safety profile of AVE1642 as single agent and the safety profile of combinations with other anti-cancer therapies of interest in liver carcinoma , including detection of immunogenicity.

- To evaluate pharmacokinetics and pharmacodynamics profiles of AVE1642 as single agent or any PK interactions when given in combination with other anti-cancer therapies.

- To assess the preliminary clinical activity in terms of response rate (Complete response + Partial response), duration of responses, stabilisation rate and duration of stabilisation, according to RECIST criteria.

- To assess the biological activity at the tumor level.


Clinical Trial Description

AVE1642 will be administered as an IV infusion on day 1 and then every 3 weeks for at least 2 infusions for evaluability requirements. Curative and / or prophylactic management of allergic reactions during infusion will be implemented when needed. The duration of the study for one patient will include a period for inclusion of up to 2 weeks, at least 2 cycles of treatment in dose escalation step (one cycle of AVE1642 alone and at least one cycle of AVE1642 in combination) and at least one cycle of the combination in the extension cohort, followed, when possible, by a minimum of 30-day follow-up after the last drug administration, in order to detect any potential immunogenicity. In the second step, the patients will continue treatment until disease progression, unacceptable toxicity or willingness to stop.

The expected enrolment period is 15 months with at least 30 day follow-up after the last patient treated. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00791544
Study type Interventional
Source Sanofi
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date November 2008
Completion date November 2009

See also
  Status Clinical Trial Phase
Terminated NCT01020812 - Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT04443322 - Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 ) N/A
Completed NCT02305459 - CIRSE Registry for SIR-Spheres Therapy
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Completed NCT02424955 - Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation N/A
Completed NCT03775863 - AFP Model and Liver Transplantation.
Not yet recruiting NCT04825470 - Liver Transplantation for Unresectable GIST Liver Metastases N/A
Recruiting NCT06144385 - A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma Phase 1
Completed NCT01717729 - Hepatocellular Carcinoma Treated With Iodine-125 Implantation Phase 3
Completed NCT03178409 - Combined HCC-MFCCC N/A
Suspended NCT04955808 - Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Recruiting NCT01380392 - The Illness of Uncertainty, Personality and Coping Strategies in Patients With Hepatocellular Carcinoma N/A
Withdrawn NCT01744639 - Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation N/A
Completed NCT01482442 - SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma Phase 3
Active, not recruiting NCT01272557 - Sorafenib Plus Doxorubicin Versus Sorafenib Alone for the Treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II Trial Phase 2
Completed NCT00328770 - De Novo Sirolimus-based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma Phase 2/Phase 3
Completed NCT05681234 - Clinical Application of 18F-labeled RD2 PET/CT Imaging in the Diagnosis and Treatment of Small Liver Carcinoma N/A
Terminated NCT00767234 - Permission to Collect Blood Over Time for Research N/A
Active, not recruiting NCT02465060 - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Phase 2
Recruiting NCT04288323 - Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis Phase 4